June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Title ; Does anti VEGF is a promising modalityof treatment in Dry eye disease?
Author Affiliations & Notes
  • Dr Ajay kartik Ambade
    Eye, Ambade Eye Hospital, Nagpur, Maharashtra, India
  • dr Rakhee A Ambade
    PHYSIOLOGY, LATA MANGESHKAR HOSPITAL, INDIA, MAHARASHATRA, India
  • Footnotes
    Commercial Relationships   Dr Ajay Ambade, None; dr Rakhee Ambade, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2653. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Dr Ajay kartik Ambade, dr Rakhee A Ambade; Title ; Does anti VEGF is a promising modalityof treatment in Dry eye disease?. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2653.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Aim ; To evalute tear film stability and tear production in dry eye diseased patients treated with intravitreal antiVEGF(avastin )for diabetic macular edema and hence studing the hypothesis of anti VEGF in treatment of Dry eye diseased.

Methods : Method ;21 dry eye diseased patients with CSMEtreated with anti VEGFwere studied for tear film stability and tearfilm stability and tear production . The non injected eye were taken for the controlled group of the study..Tear film break-up time (TBUT),and Schirmer 1 test (S1T) were mearsed at 1,30,90and 180th days after the injecetion.

Results : Result: The raised mean tear film breakup time indicates the increased stability of tear film in post anti VEGF (Avastn ) injected eyes. The higher Schirmer 1 test value indicates improvement in tear production in the anti VEGF (Avastin) group patients.

Conclusions : Conclusion: ;post injection of anti VEGF show distinct sings of improvments in dry eye disease in early periods of follwup.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×